Top 12 Viral Vector Manufacturing Companies in the World

The global viral vector manufacturing market size reached US$ 1,200.1 Million in 2023. As per the analysis by IMARC Group, the top viral vector manufacturing companies are increasingly focusing on investments in R&D to focus on improving vector production processes and enhancing the vector quality. The major market players are investing in advanced technologies and innovative manufacturing platforms enabling the scalable and cost-effective production of viral vectors. Moreover, the escalating demand for viral vectors in gene therapy and vaccine development is also creating lucrative growth opportunities for the market players. In addition to this, manufacturers are expanding their manufacturing capacities, including the construction of new manufacturing facilities and the expansion of existing ones to accommodate larger-scale manufacturing. Also, the top players are adhering to good manufacturing practices (GMP), investing in quality control systems and implementing process validations to guarantee the efficacy of viral vectors. They are also focusing on leveraging strategic partnerships, mergers and acquisitions (M&As) and collaborations with research organizations, biopharmaceutical companies and academic institutions for accessing novel technologies and developing new therapies. Some of the other factors contributing to the market include rising medical expenditure, growing prevalence of various viral diseases, inflating disposable income levels, and continual technological advancements in vector manufacturing processes. By 2028, the market to reach US$ 7,681.6 Million by 2032, exhibiting a growth rate (CAGR) of 22.4% during 2024-2032.

Learn about opportunities, challenges, and trends in the global Viral Vector Manufacturing market with IMARC’s market research report. Try a free sample today!

List of Top Companies Operating in the Viral Vector Manufacturing Industry Worldwide:

The global viral vector manufacturing market has several major players including Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V. More information about these companies has been provided below.

1. Cognate BioServices Inc. (Charles River Laboratories International Inc.)

Cognate BioServices Inc, founded in 2002, is one of the leading players in the viral vector manufacturing market, and is now a part of Charles River Laboratories International Inc. The company specializes in contract development and manufacturing services for advanced therapeutics, which includes viral vectors used in gene and cell therapy applications. The company provides end-to-end viral vector manufacturing solutions, ranging from process development, manufacturing, quality control, to regulatory support. Their portfolio includes adeno-associated viruses (AAV), lentiviruses, retroviruses, and other viral vectors. Cognate BioServices also offers customized solutions, quality assurance, and analytical testing, and product characterization for a wide range of viral vectors as well as compliance with regulatory guidelines.

2. F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG, commonly known as Roche, is a major player in the global pharmaceutical and biotechnology industry with an enhanced focus in the development of innovative medicines and diagnostics. The company utilizes viral vectors in research and development (R&D) activities, particularly in the field of gene therapy, although it is not primarily engaged in large-scale commercial viral vector manufacturing. The company specializes in oncology, immunology, infectious diseases, neuroscience, and rare diseases treatment. Additionally, Roche has established strategic partnerships and collaborations with other organizations specializing in viral vector manufacturing as well as third-party manufacturers for their commercial operations.

3. FinVector Oy

Founded in 1993, Finvector Oy is a leading global provider of FinVector biotechnology services that specializes in the development and manufacturing of viral vectors for gene therapy and vaccine applications. The company specializes in the production of various viral vectors, including adenoviral vectors, lentiviral vectors, and adeno-associated viral (AAV) vectors. FinVector Oy encompasses the entire viral vector manufacturing process, from vector design and development to large-scale production. As a viral vector manufacturing manufacturer, the company focuses on ensuring the highest quality and safety standards in vector production, adhering to regulatory guidelines and Good Manufacturing Practices (GMP). FinVector Oy serves a large customer base which include biotechnology and pharmaceutical companies, academic institutions, and research organizations that are engaged in gene therapy and vaccine development. 

4. FUJIFILM Holdings Corporation

Fujifilm Holdings Corporation, commonly known as Fujifilm, is a multinational conglomerate with diverse business operations. While Fujifilm is recognized for its expertise in imaging and photography, the company has expanded its operations in the viral vector manufacturing sector. Fujifilm Diosynth Biotechnologies, a subsidiary of FUJIFILM Holdings Corporation, specializes in contract development and manufacturing services for viral vectors used in gene therapies and vaccines and has gained reputation for its high-quality manufacturing processes and regulatory compliance. Fujifilm leverages its proprietary technologies and expertise to deliver integrated cell culture processes, purification, and viral vector production in a closed and automated system.

5. Kaneka Eurogentec S.A. (Kaneka Corporation)

Kaneka Eurogentec S.A., a subsidiary of Kaneka Corporation, is a Belgium-based multinational chemical and biotechnology company with diverse business operations. The company specializes in producing high-quality adeno-associated virus (AAV) vectors for gene therapy applications, thereby offering a comprehensive range of services encompassing process development, scale-up, purification, and quality control. In addition to this, employs state-of-the-art facilities and cutting-edge technologies to support end-to-end viral manufacturing process. The company maintains a strong global presence through an extensive sales network and partnerships, and establishing strategic partnerships with companies and research institutions worldwide to facilitate the manufacturing of viral vectors for gene therapy applications.

6. Lonza Group AG

Lonza Group AG is a is a Swiss-based multinational company specializing in the life sciences and healthcare industry and a leading provider of contract development and manufacturing services for biopharmaceuticals. The company specializes encompasses the entire life cycle of viral vector manufacturing, with an expertise in the manufacturing of lentiviral vectors, adenoviral vectors, and adeno-associated viral vectors (AAV). The company operates through several business segments, including pharma, biotech, nutrition and consumer health. Lonza Group encompasses viral vector manufacturing, cell and gene therapy manufacturing, process development, and regulatory support. In addition to this, Lonza Group also provides process optimization, analytical development, viral vector production using suspension and adherent cell cultures, and downstream purification processes.

7. Merck KGaA

Merck KGaA, also known as Merck Group, is a leading multinational pharmaceutical, chemical, and life sciences company that holds a significant share in the global viral vector manufacturing market. The company is a leading provider of viral clearance technologies, process development, as well as analytical tools for quality control to support the process development, scale-up, and commercial manufacturing of viral vectors. Merck KGaA also leverages its viral and gene therapy services to provide contract manufacturing and process development expertise, ensuring regulatory compliance and quality control to support scalable production. Apart from viral vector manufacturing, the company is involved in various sectors, including healthcare, life sciences, and performance materials.

8. Oxford Biomedica plc

Oxford Biomedica plc is a key player in the global viral vector manufacturing market that has expertise in the development and manufacturing of lentiviral vectors used in gene and cell therapies. The company operates in advanced manufacturing facilities in Oxford, UK, adhering to stringent regulatory requirements and GMP standards. Additionally, Oxford Biomedica employs advanced technologies in the development and production of high-quality vectors for use in gene and cell therapies, including CAR-T cell therapies and gene editing applications. The company invests heavily in R&D activities dedicated to expanding the applications of lentiviral vectors in emerging therapeutic areas, and has made significant investments in expanding its capacity. The company serves clients and partners across Europe, North America, and Asia-Pacific.

9. REGENXBIO Inc.

REGENXBIO Inc. is a leading biotechnology company that has expertise in the development, manufacturing, and commercialization of gene therapies. The company specializes in viral vector design, engineering, and manufacturing. With an enhanced focus on the development of its proprietary adeno-associated virus (AAV) gene delivery platform, the company develops potential treatments for various genetic disorders and other therapeutic areas. In addition to this, REGENXBIO Inc. has also established strategic partnerships and collaborations with other companies in the biotechnology and pharmaceutical industries.

10. Sanofi S.A.

Sanofi S.A. is a global pharmaceutical company that operates in various therapeutic areas, including vaccines and gene therapies. Through its subsidiary Sanofi Genzyme, that focuses on rare diseases and specialty care, the company has gained a reputation for commercial viral vector manufacturing. Sanofi Genzyme actively conducts research and development to advance the manufacturing and development of viral vectors for gene therapy applications, aiming to enhance gene therapies for various diseases. The corporation covers major therapeutic areas including cardiovascular, central nervous system, diabetes, internal medicine, oncology, and thrombosis. The company has a strong business presence in Europe, North America, and Asia-Pacific.

11. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a leading force in the global viral manufacturing market, providing comprehensive services to provide unparalleled support for viral manufacturing processes. The company offers a comprehensive range of tailored solutions, critical technologies, and tools for efficient and scalable viral manufacturing. Their portfolio includes viral vector production, viral vaccine manufacturing, and viral gene therapy production and advanced bioprocessing technologies, such as cell culture media, cell culture systems, and bioreactors. Furthermore, the company has gained a reputation for its commitment to quality and regulatory compliance is evident through their adherence to Good Manufacturing Practices (GMP), technical assistance, training, and validation services.

12. uniQure N.V.

uniQure N.V. is a Dutch biopharmaceutical company that emphasizes on the development, production, and commercialization of gene therapies for severe genetic diseases. The company has a diverse pipeline of gene therapies targeting various diseases, such as hemophilia, Huntington's disease, and cardiovascular disorders. uniQure N.V. utilizes viral vector technology, particularly adeno-associated virus (AAV) vectors, for the delivery of therapeutic genes into target cells. Furthermore, the company engages in strategic collaborations and partnerships with research institutions and biopharmaceutical companies to leverage expertise and expand research capabilities. The company is headquartered in Netherlands, and has a significant business presence in Europe and North America.

Get an inside look at the global viral vector manufacturing market with exclusive insights, including:

• CAGR projections during the 2023-2028 forecast period
• In-depth information on the factors that will fuel the viral vector manufacturing market growth in the next five years.
• Precise predictions regarding upcoming trends and potential changes in consumer behavior
• Analysis of the viral vector manufacturing industry's expansion at the regional and global level.
• A thorough review of the market's competitive landscape and detailed information on key players
• Detailed explanations of the challenges that could impede the growth of the viral vector manufacturing market.

About Author: